About: Testing of natural products in clinical trials targeting the SARS-CoV-2 (Covid-19) Viral Spike Protein-Angiotensin Converting Enzyme-2 (ACE2) interaction

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Testing of natural products in clinical trials targeting the SARS-CoV-2 (Covid-19) Viral Spike Protein-Angiotensin Converting Enzyme-2 (ACE2) interaction Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Testing of natural products in clinical trials targeting the SARS-CoV-2 (Covid-19) Viral Spike Protein-Angiotensin Converting Enzyme-2 (ACE2) interaction
Creator	Kerimi, Asimina Williamson, Gary
source	Elsevier; Medline; PMC
abstract	Commonly used drugs for treating many conditions are either natural products or derivatives. In silico modelling has identified several natural products including quercetin as potential highly effective disruptors of the initial infection process involving binding to the interface between the SARS-CoV-2 (Covid-19) Viral Spike Protein and the epithelial cell Angiotensin Converting Enzyme-2 (ACE2) protein. Here we argue that the oral route of administration of quercetin is unlikely to be effective in clinical trials owing to biotransformation during digestion, absorption and metabolism, but suggest that agents could be administered directly by alternative routes such as a nasal or throat spray.
has issue date	2020-06-25(xsd:dateTime)
bibo:doi	10.1016/j.bcp.2020.114123
bibo:pmid	32593613
has license	no-cc
sha1sum (hex)	e8101b9d93cfefde48e94aeebc21ea203645ad5a
schema:url	https://doi.org/10.1016/j.bcp.2020.114123
resource representing a document's title	Testing of natural products in clinical trials targeting the SARS-CoV-2 (Covid-19) Viral Spike Protein-Angiotensin Converting Enzyme-2 (ACE2) interaction
has PubMed Central identifier	PMC7316054
has PubMed identifier	32593613
schema:publication	Biochem Pharmacol
resource representing a document's body	covid:e8101b9d93cfefde48e94aeebc21ea203645ad5a#body_text
is schema:about of	named entity 'natural products' named entity 'Journal' named entity 'Testing' named entity 'Covid-19' named entity 'clinical trials' named entity 'ADAM' named entity 'TMPRSS2' named entity 'clinical trials' named entity 'action' named entity 'natural products' named entity 'Commentary' named entity 'Testing' named entity 'Transmembrane protease, serine 2' named entity 'ADAM' named entity 'ACE2' named entity 'metallopeptidase' named entity 'clinical trials' named entity 'SARS-CoV-2' named entity 'Viral' named entity 'Angiotensin Converting Enzyme' named entity 'SARS-CoV-2' named entity 'ACE2' named entity 'clinical trials' named entity 'natural products' named entity 'delivery method' named entity 'molecular form' named entity 'bioactive compound' named entity 'plasma' named entity 'quercetin' named entity 'virus' named entity 'allergic rhinitis' named entity 'quercetin' named entity 'cell entry' named entity 'glucoside' named entity 'Quercetin' named entity 'Quercetin' named entity 'Covid' named entity 'effective dose' named entity 'natural products' named entity 'nasal spray' named entity 'ACE2' named entity 'quercetin' named entity 'cardiovascular health' named entity 'infection' named entity 'Viral' named entity 'quercetin' named entity 'attenuate' named entity 'Quercetin' named entity 'clinical trials' named entity 'small molecule' named entity 'quercetin' named entity 'Covid-19' named entity 'enzyme' named entity 'moiety' named entity 'quercetin' named entity 'naturally occurring' named entity '3C-like protease' named entity 'orders of magnitude' named entity 'lung cancer' named entity 'United States Food and Drug Administration' named entity 'spike protein' named entity 'aglycone' named entity 'metabolism' named entity 'plasma' named entity 'SARS-CoV' named entity 'quercetin' named entity 'ACE2' named entity 'association constant' named entity 'quercetin' named entity 'solubility' named entity 'digestion' named entity 'quercetin' named entity 'flavonoids' named entity 'Viral' named entity 'quercetin' named entity 'Spike Protein' named entity 'metabolic' named entity 'quercetin' named entity 'nasal spray' named entity '8,000'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software